XBiotech appoints Sushma Shivaswamy and Jan-Paul Simard as co-CEOs

What happened

XBiotech appointed Dr. Sushma Shivaswamy and Jan-Paul Simard as co-chief executive officers, effective October 23, 2026. Shivaswamy continues as Chief Scientific Officer, and Simard moves from research and clinical development roles into the co-CEO position.

Confirmed

Global impact / market context

Splitting the top job between a longtime scientific leader and a clinical development veteran may keep research and study execution closely tied to daily decision-making. Shivaswamy also retains her scientific role, so company strategy may lean toward advancing its experimental treatments rather than commercial or financial priorities.

Analyst inference

Leadership changes at small drug developers often draw investor attention because early-stage companies depend heavily on a few key people. Simard's employment agreement includes a $150,000 annual base salary and 2,000,000 stock options vesting over three years, tying part of his pay to long-term share performance.

Analyst inference

What to watch

1. Simard's employment agreement starts October 26, 2026, pays a $150,000 annual base salary prorated through 2026 and continuing through 2027, and includes 2,000,000 stock options vesting over three years. Confirmed
2. Watch whether the company later discloses why it chose a shared chief executive structure and how duties are divided between the two co-CEOs, since the filing does not state a reason for the appointments. Proposed
3. Track whether Shivaswamy's combined scientific and co-CEO roles change research spending or trial timelines, and whether Simard's clinical background shifts study design decisions that could affect future revenue prospects. Analyst inference

Evidence

• Original source link unavailable